<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1803257093
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROMAX 500 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        62.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cipromax belongs to a group of antibiotics known as quinolones. It has high anti-bacterial activity.</p><p>Cipromax works by killing bacteria that cause infections. It only works against specific strains of bacteria.</p><p>Adults:</p><p>Cipromax is used to treat the following bacterial infections:</p><p>&bull; respiratory tract infections(e.g. certain types of pneumonia)</p><p>&bull; long lasting or recurring ear or sinus infections</p><p>&bull; urinary tract infections (bladder and kidneys infection)</p><p>&bull; infections of the testicles</p><p>&bull; genital organ infections in women(e.g. gonorrhoea, a sexually transmitted disease)</p><p>&bull; gastro-intestinal tract infections (e.g.severe gastro-enteritis) and intra-abdominal infections</p><p>&bull; skin and soft tissue infections</p><p>&bull; bone and joint infections</p><p>&bull; to treat infections in patients with a very low white blood cell count (neutropenia)</p><p>&bull; to prevent infections in patients with a very low white blood cell count (neutropenia)</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull; to prevent infections due to the bacteria Neisseria meningitides which causes meningitis(brain and spinal cord inflammation)</p><p>&bull; anthrax inhalation exposure (infection that occurs when the spores from bacteria Bacillus anthracis enters the body).</p><p>&nbsp;</p><p>Cipromax may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection.</p><p>If you have a severe infection or one that is caused by more than one type of bacteria, you may be given additional antibiotic treatment in addition to Cipromax.</p><p>Children and adolescents:</p><p>Cipromax should be used under specialist medical supervision, to treat the following bacterial infections for children and adolescents:</p><p>&bull; lung and bronchial infections in children and adolescents suffering from cystic fibrosis (genetic disorder known to be an inherited disease of the secretory glands, including the glands that make mucus and sweat).</p><p>&bull; complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis).</p><p>&bull; anthrax inhalation exposure (infection that occurs when the spores from bacteria Bacillus anthracis enters the body).</p><p>&nbsp;</p><p>Cipromax may also be used to treat other specific severe infections in children and adolescents when your doctor considers this as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Cipromax if you:</p><p>&bull; are allergic (hypersensitive) to the Ciprofloxacin, to any other quinolone drugs or to any of the other ingredients of Cipromax tablets (see section 6).</p><p>&bull; are taking tizanidine (see Section 2: Taking other medicines).</p><p>&nbsp;</p><p>Take special care with Cipromax Tablets:</p><p>Before taking Cipromax Tablets, tell your doctor if:</p><p>&bull; You suffer from &lsquo;fits&rsquo; or epilepsy or any other neurological conditions.</p><p>&bull; You have ever had kidney problems because your treatment may need to be adjusted</p><p>&bull; You have a history of tendon problems during previous treatment with antibiotics such as Cipromax. Stop taking Cipromax immediately and get medical help right away.</p><p>&bull; You have myasthenia gravis (a type of muscle weakness). Cipromax should not be used in patients who have a known history of myasthenia gravis.</p><p>&bull; You have nerve problems; Cipromax should not be used in patients who have a history of a nerve problem called peripheral neuropathy.</p><p>&bull; You have a history of abnormal heart rhythms (arrhythmias).</p><p>&nbsp;</p><p>Heart problems</p><p>&bull; Caution should be taken when using this kind of medicine, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have</p><p>a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly</p><p>&nbsp;</p><p>&nbsp;</p><p>or you are taking other medicines that result in abnormal ECG changes (see section Taking other medicines).</p><p>&nbsp;</p><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to cipromax. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p>Contact your doctor immediately, if any of the following occurs while taking Cipromax. Your doctor will decide whether treatment with Cipromax needs to be stopped.</p><p>&bull; Severe, sudden allergic reaction (an anaphylactic shock, angio-oedema). Even with the first dose, there is a small chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, sick or faint, or experiencing dizziness when standing up. If this happens, stop taking Cipromax tablets and contact your doctor immediately.</p><p>&bull; Pain and swelling in the joints and tendinitis may occur occasionally, particularly if you are elderly and are also being treated with corticosteroids. Inflammation and ruptures of tendons may occur even within the first 48 hours of treatment or up to several months after discontinuation of Cipromax tablets therapy. At the first sign of any pain or inflammation stop taking Cipromax tablets and rest the painful area. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture.</p><p>&bull; If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If this happens, stop taking Cipromax tablets and contact your doctor immediately.</p><p>&bull; You may experience psychiatric reactions the first time you take Cipromax tablets. If you suffer from depression or psychosis, your symptoms may become worse under treatment with Cipromax tablets. In rare cases, depression or psychosis can progress to thoughts of suicide, suicide attempts, or completed suicide. If this happens, stop taking Cipromax tablets and contact your doctor immediately.</p><p>&bull; You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or weakness. If this happens, stop taking Cipromax tablets and contact your doctor immediately.</p><p>*All antibacterial fluoroquinolone drugs taken by mouth or by injection can cause permanent nerve damage.</p><p>&bull; Diarrhoea may develop while you are taking antibiotics, including Cipromax tablets, or even several weeks after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking Cipromax tablets immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements and contact your doctor.</p><p>&bull; Tell the doctor or laboratory staff that you are taking Cipromax tablets if you have to provide a blood or urine sample.</p><p>&bull; If you suffer from kidney problems, tell the doctor because your dose may need to be adjusted.</p><p>&bull; Cipromax tablets may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, stop taking Cipromax tablets and contact your doctor immediately.</p><p>&bull; Cipromax tablets may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as</p><p>sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.</p><p>&bull; Tell your doctor if you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anemia with Cipromax.</p><p>&bull; Your skin becomes more sensitive to sunlight or ultraviolet (UV) light when taking Cipromax tablets. Avoid exposure to strong sunlight, or artificial UV light such as sunbeds.</p><p>&nbsp;</p><p>Taking other medicines:</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those medicines obtained without a prescription.</p><p>You must tell your doctor if you are taking other medicines that can alter your heart rhythm: medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.</p><p>Do not take Cipromax together with tizanidine, because this may cause side effects such as low blood pressure and sleepiness (see Section 2: &quot;Do not take Cipromax&quot;).</p><p>The following medicines are known to interact with Cipromax in your body. Taking Cipromax together with these medicines can influence the therapeutic effect of those medicines. It can also increase the probability of experiencing side effects.</p><p>Tell your doctor if you are taking:</p><p>&bull; xanthine derivatives such as theophylline (used to treat asthma)</p><p>&bull; phenytoin (used to treat epilepsy)</p><p>&bull; any drugs which thin the blood (known as anti-coagulants e.g. warfarin)</p><p>&bull; cyclosporin (used to treat psoriasis, dermatitis, rheumatoid arthritis and in organ transplantation)</p><p>&bull; glibenclamide (an oral drug used to treat diabetes)</p><p>&bull; probenecid (used to prevent gout)</p><p>&bull; metoclopramide (used to treat nausea and vomiting (feeling/being sick) and migraine)</p><p>&bull; mexiletine (used to treat abnormal heart beats)</p><p>&bull; ropinirole (used to treat Parkinson&rsquo;s disease)</p><p>&bull; methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)</p><p>&bull; tizanidine (for muscle spasticity in multiple sclerosis)</p><p>&bull; clozapine (an antipsychotic)</p><p>&bull; olanzapine (an antipsychotic)</p><p>&bull; other medicines that can alter your heart rhythm: medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.</p><p>&nbsp;</p><p>Cipromax may increase the levels of the following medicines in your blood:</p><p>&bull; pentoxifylline (for circulatory disorders)</p><p>&bull; caffeine</p><p>&bull; duloxetine (for depression, diabetic nerve damage or incontinence)</p><p>&bull; lidocaine (for heart conditions or anesthetic use)</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull; sildenafil (e.g. for erectile dysfunction)</p><p>&nbsp;</p><p>Some medicines reduce the effect of Cipromax. Tell your doctor if you take or wish to take:</p><p>&bull; antacids</p><p>&bull; omeprazole</p><p>&bull; mineral supplements</p><p>&bull; sucralfate</p><p>&bull; a polymeric phosphate binder (e.g. sevelamer)</p><p>&bull; medicines or supplements containing calcium, magnesium, aluminium or iron {e.g. didanosine tablets (an antiviral drug used to treat HIV)}</p><p>&nbsp;</p><p>If these medicines are essential, take Cipromax about two hours before or no sooner than four hours after them.</p><p>Taking Cipromax with food and drink</p><p>Unless you take Cipromax during meals, do not eat or drink any dairy products (e.g. milk or yogurt) or drinks with added calcium. These can affect the absorption of cipromax and so you should take your tablets either 1 to 2 hours before or at least 4 hours after you have such products.</p><p>Pregnancy and breast-feeding</p><p>It is preferable to avoid the use of Cipromax during pregnancy. Tell your doctor if you are pregnant or planning to become pregnant.</p><p>Do not take Cipromax tablets during breast feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.</p><p>Ask your doctor or pharmacist for advice before taking any other medicine.</p><p>Driving and using machines</p><p>Cipromax may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to Cipromax before driving a vehicle or operating machinery. If in doubt, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Cipromax tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>The tablets should always be taken with plenty of water, as this will help to prevent the formation of tiny crystals in your urine (crystalluria).</p><p>You can take the tablets at meal times or between meals. Any calcium you take as a part of a meal will not seriously affect uptake. However, do not take cipromax tablets with dairy products such as milk or yogurt or with fortified fruit juices (eg.Calcium-fortified orange juice).</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p>Your dose will be dependent on the type and severity of your infection, your age, weight and kidney function.</p><p>Adults</p><p>The usual adult dose is between 100 &ndash; 750mg twice daily. In Respiratory infections the usual dose is 500mg-750mg twice daily. In infections of the bladder and kidneys, the usual dose is 250 - 500mg twice daily. In gonorrhoea, the usual dose is 250 - 500mg as a single dose. In gastro-intestinal infections, the usual dose is 500 mg twice daily. In intra-abdominal infections, skin and soft tissue infections, bone and joint infections, and in neutropenic patients the usual dose is 500-</p><p>750mg twice daily. In infections due to Bacterium Neisseria meningitidis the usual dose is 500mg as a single dose. Inhalation anthrax exposure the usual dose is 500mg twice daily.</p><p>Elderly Patients</p><p>Your doctor will decide what dose to give you. This may be lower than the usual adult dose depending on the severity of your infection and your kidney function.</p><p>Kidney/Liver problems</p><p>Your doctor will decide what dose to give you depending on your kidney and liver function. Special dosing instructions are needed if you are on haemodialysis or having (continuous peritoneal dialysis).</p><p>Children and adolescents</p><p>The use of Cipromax Tablets is not generally recommended in children. However in some cases treatment with these tablets is of benefit and your doctor may decide to treat your child with this drug particularly for the below mentioned infections.</p><p>&middot; Cystic fibrosis the usual dose is 20mg/kg body weight twice daily with a maximum daily dose of 750 mg.</p><p>&middot; Complicated urinary tract infections and pyelonephritis the usual dose is 10 to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p><p>&middot; Inhalation anthrax exposure the usual dose is 10 to 15 mg/kg body weight twice daily with a maximum of 500mg per dose.</p><p>&middot; Other severe infections the usual dose is 20mg /kg body weight twice daily with a maximum of 750mg per dose.</p><p>&nbsp;</p><p>Do not skip any doses of Cipromax, or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless:</p><p>&nbsp;</p><p>&middot; You have nerve problems. See &ldquo;2. BEFORE YOU TAKE CIPROMAX&rdquo;</p><p>&middot; You have central nervous system problems. See &ldquo;2. BEFORE YOU TAKE CIPROMAX&rdquo;</p><p>It is very important that you follow your doctor&rsquo;s instructions as to how many Cipromax Tablets to take, how often to take them and for how long you should continue to take your tablets. The normal duration of treatment is between 5 to 21 days (although this may be longer), depending on the type and severity of infection.</p><p>If you take more Cipromax tablets than you should</p><p>If you or someone else swallows several of these tablets all together, or you think a child has swallowed any of these tablets, contact your doctor or pharmacist or hospital emergency department immediately. Always take any tablets left over with you, also the box and leaflet as this will allow easier identification of the tablets.</p><p>If you forget to take Cipromax tablets</p><p>If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose and just carry on as before. Do not take a double dose to make up for a forgotten dose. Be sure to complete your course of treatment.</p><p>If you stop taking Cipromax tablets</p><p>It is important that you finish the course of treatment even if you begin to feel better after a few days. If you stop taking this medicine too soon your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Cipromax can cause side-effects, although not everybody gets them.</p><p>About 5 &ndash;14% of patients have side-effects and the most common side-effects involve the gut and the nervous system.</p><p>If any of the following symptoms occur soon after taking your tablets, stop taking the tablets and tell your doctor immediately. This kind of reaction is rare and may mean you are suffering from an allergic reaction to the medicine:</p><p>&bull; Rash, itching, a lumpy skin rash (&lsquo;hives&rsquo;), fever, small red spots on the body, increased sensitivity to sunlight or very rarely severe skin reactions such as large fluid filled blisters, peeling, sores and ulceration. Ulceration can also occur in the mouth and throat, around the anus and genital region and on the surface of the eyes</p><p>&bull; Sudden wheeziness or tightness of the chest</p><p>&bull; Swelling of the eyelids, face, lips or blood vessels in the skin</p><p>&bull; Sickness and headache</p><p>&nbsp;</p><p>You should also tell your doctor immediately and stop taking your tablets if you notice:</p><p>&bull; Pain or inflammation in the tendons. This effect occurs in isolated cases. If these symptoms are experienced you should stop taking your tablet, rest the affected limb and consult your doctor immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull; Severe diarrhoea with bleeding or mucus. This effect occurs in less than one in a thousand but more than one in ten thousand people.</p><p>&bull; A feeling that you want to physically harm yourself. This only occurs in isolated cases.</p><p>&middot; Changes in sensation and nerve damage (Peripheral Neuropathy that may be irreversible) &ndash; damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including Cipro.</p><p>&nbsp;</p><p>&nbsp;</p><p>Other possible side-effects, which may occur, are listed below:</p><p>Common side effects (between 1 and 10 in every 100 people are likely to get these):</p><p>&bull; nausea, diarrhoea</p><p>&bull; Joint pains in children</p><p>&nbsp;</p><p>Uncommon side effects (between 1 and 10 in every 1,000 people are likely to get these):</p><p>&bull; fungal superinfections</p><p>&bull; a high concentration of eosinophils, a type of white blood cell</p><p>&bull; loss of appetite (anorexia)</p><p>&bull; hyperactivity or agitation</p><p>&bull; headache, dizziness, sleeping problems, or taste disorders</p><p>&bull; vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/ heartburn), or wind</p><p>&bull; increased amounts of certain substances in the blood (transaminases and/or bilirubin)</p><p>&bull; rash, itching, or hives</p><p>&bull; poor kidney function</p><p>&bull; pains in your muscles and bones, feeling unwell (asthenia), or fever</p><p>&bull; increase in blood alkaline phosphatase (a certain substance in the blood)</p><p>&nbsp;</p><p>Rare side effects (between 1 and 10 in every 10,000 people are likely to get these):</p><p>&bull; inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section 2: Take special care with Cipromax)</p><p>&bull; changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or</p><p>&nbsp;</p><p>decreased amounts of a blood clotting factor (thrombocytes)</p><p>&bull; allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angioedema)</p><p>&bull; increased blood sugar (hyperglycaemia)</p><p>&bull; confusion, disorientation, anxiety reactions, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide), or hallucinations</p><p>&bull; pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, seizures (see Section 2: Take special care with Cipromax), or giddiness</p><p>&bull; eyesight problems including double vision</p><p>&bull; tinnitus, loss of hearing, impaired hearing</p><p>&bull; rapid heartbeat (tachycardia)</p><p>&bull; expansion of blood vessels (vasodilation), low blood pressure, or fainting</p><p>&bull; shortness of breath, including asthmatic symptoms</p><p>&bull; liver disorders, jaundice (cholestatic icterus), or hepatitis</p><p>&bull; sensitivity to light (see Section 2: Take special care with Cipromax)</p><p>&bull; muscle pain, inflammation of the joints, increased muscle tone, or cramp.</p><p>&bull; kidney failure, blood or crystals in the urine (see Section 2: Take special care with Cipromax),urinary tract inflammation</p><p>&bull; fluid retention or excessive sweating</p><p>&bull; increased levels of the enzyme amylase</p><p>&nbsp;</p><p>Very rare side effects (less than 1 in every 10,000 people are likely to get these):</p><p>&bull; migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure)</p><p>&bull; a special type of reduced blood cell count {(haemolytic anaemia)-a form of anaemia due to the breaking down of red blood cells,} may occur with jaundice), a dangerous drop in a type of white blood cells (agranulocytosis ); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2: Take special care with Cipromax)</p><p>&bull; severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatal) (see Section 2: Take special care with Cipromax)</p><p>&bull; mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide) (see Section 2: Take special care with Cipromax)</p><p>&bull; visual colour distortions</p><p>&bull; inflammation of the wall of the blood vessels (vasculitis)</p><p>&bull; pancreatitis</p><p>&bull; small, bleeding under the skin (petechiae); various skin eruptions or rashes (for example, the potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis)</p><p>&bull; muscle weakness, tendon inflammation, tendon rupture &ndash; especially of the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Take special care with Cipromax); worsening of the symptoms of myasthenia gravis (see Section 2: Take special care with Cipromax)</p><p>&nbsp;</p><p>Frequency not known (cannot be estimated from the available data)</p><p>&bull; troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities</p><p>&bull; abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart)</p><p>&bull; pustular rash</p><p>&bull; influence on blood clotting (in patients treated with Vitamin K antagonists)</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&ordm;C.</p><p>Keep out of the reach and sight of children.</p><p>Do not use yo</p><p>Medicines should not be disposed of via waste water or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient:</p><p>Cipromax 500 mg film-coated tablets: Each Film-coated tablet contains Ciprofloxacin Hydrochloride Monohydrate equivalent to 500mg Ciprofloxacin as an active ingredient</p><p>The Other ingredients are:</p><p>Tablet Core: Ciprofloxacin Hydrochloride, Avicel PH 101, Sodium Starch Glycolate, Povidone K-30, Colloidal Silicon Dioxide and Magnesium Stearate.</p><p>Tablet Coat:</p><p>&middot; Cipromax 500mg film-coated tablets</p><p>OPADRY OY-L-30902 Blue</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cipromax 500 mg film-coated tablets: A light blue oblong, biconvex film-coated tablet engraved with "SP 150" on one side and breakline on the other side. Each unit carton contains 10 film-coated tablets in one blister strip.
Contents of the pack
Cipromax 500 mg film-coated tablets:

· Are available in blister packs.

· Pack sizes of 10, 100 and 1000 film-coated tablets. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي سيبروماكس إلى مجموعة من المضادات الحيوية تعرف باسم الكينولونات. والتى لها نشاط عالى مضاد للبكتيريا. سيبروماكس يعمل على قتل البكتيريا المسببة للعدوى. وهو يعمل فقط ضد سلالات معينة من البكتيريا.</p><p>فى حالة البالغين:</p><p>يستخدم سيبروماكس لعلاج العدوى البكتيرية الآتية:</p><p>&middot; عدوى الجهاز التنفسى (مثل أنواع معينة من الالتهاب الرئوي)</p><p>&middot; العدوى طويلة المدى أو المتكررة التى تصيب الأذن أو الجيوب الأنفية.</p><p>&middot; التهابات المسالك البولية (عدوى المثانة والكلى)</p><p>&middot; التهابات الخصيتين</p><p>&middot; العدوى التى تصيب الجهاز التناسلي عند النساء (مثل السيلان والأمراض التي تنتقل عن طريق الاتصال الجنسي)</p><p>&middot; التهابات المسالك الهضمية (مثل الالتهاب الحاد للمعدة والأمعاء) والتهابات داخل البطن</p><p>&middot; العدوى التى تصيب الجلد والأنسجة اللينة</p><p>&middot; العدوى التى تصيب العظام والمفاصل</p><p>&middot; لعلاج العدوى عند المرضى الذين يعانون من انخفاض حاد فى عدد خلايا الدم البيضاء (نقص العدلات)</p><p>&middot; للوقاية من العدوى عند المرضى الذين يعانون من انخفاض حاد فى عدد خلايا الدم البيضاء (نقص العدلات)</p><p>&middot; للوقاية من العدوى التى تسببها بكتيريا التهابات السحايا النيسيري والتي تسبب التهاب السحايا (التهاب الدماغ والنخاع الشوكي)</p><p>&middot; التعرض لاستنشاق الجمرة الخبيثة (وهى العدوى التي تحدث عند دخول بويغات من البكتيريا العصوية الجمرية إلى الجسم).</p><p>يمكن استخدام سيبروماكس فى علاج المرضى الذين يعانون من نقص فى عدد خلايا الدم البيضاء (نقص العدلات) المصابين بحمى التى يشتبه أن تكون نتيجة الإصابة بعدوى بكتيرية. فى حالة إصابتك بعدوى شديدة أو فى حالة إصابتك بأكثر من نوع واحد من البكتيريا, قد يضاف إلى علاجك مضاد حيوى آخر بالإضافة إلى سيبروماكس.</p><p>فى حالة الأطفال والمراهقين:</p><p>يجب استخدام سيبروماكس تحت إشراف الطبيب فى حالة علاج الأطفال والمراهقين من العدوى البكتيرية الآتية:</p><p>&middot; عدوى الرئة والتهابات الشعب الهوائية لدى الأطفال والمراهقين الذين يعانون من التليف الكيسي (اضطراب وراثي يعرف بأنه مرض وراثي في الغدد الإفرازية, بما فيها الغدد التي تفرز المخاط والعرق).</p><p>&middot; التهابات المسالك البولية المعقدة, بما في ذلك الإصابات التي وصلت إلى الكلى (التهاب الحويضة والكلية).</p><p>&middot; التعرض لاستنشاق الجمرة الخبيثة (وهى العدوى التي تحدث عند دخول بويغات من البكتيريا العصوية الجمرية إلى الجسم).</p><p>يمكن أيضاً استخدام سيبروماكس لعلاج أنواع أخرى معينة من العدوى الحادة لدى الأطفال والمراهقين عندما يرى الطبيب المعالج ضرورة لذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول أقراص سيبروماكس فى الحالات الآتية:</p><p>&middot; إذا كنت تعانى من فرط التحسس تجاه مادة سيبروفلوكساسين أو أى مضاد حيوى آخر من مجموعة الكينولونات أو أى مكون آخر من مكونات أقراص سيبروماكس (والمذكورة فى الفقرة 6).</p><p>&middot; إذا كنت تتناول تيزانيدين (انظر الفقرة 2: تناول أدوية أخرى).</p><p>ينبغى توخى الحذر عند تناول أقراص سيبروماكس</p><p>قبل تناول أقراص سيبروماكس, أخبر طبيبك المعالج إذا كانت تنطبق عليك أى من الحالات الآتية:</p><p>&middot; إذا كنت تعانى من نوبات أو صرع أو أى حالات عصبية أخرى.</p><p>&middot; إذا تعرضت لأى مشاكل بالكلى حيث أن ذلك قد يتطلب ضبط الجرعة الخاصة بك من العلاج.</p><p>&middot; إذا كان لديك تاريخ من الإصابة بمشاكل بالأوتار أثناء العلاج مسبقاً بمضادات حيوية مثل سيبروماكس. توقف عن تناول سيبروماكس فورا و احصل على المساعدة الطبية على الفور.</p><p>&middot; إذا كنت مصاباً بالوهن العضلى الوبيل (وهو نوع من ضعف العضلات).لا ينبغي استخدام سيبروماكس للمرضى الذين لديهم تاريخ معروف من الوهن العضلى الوبيل.</p><p>&middot; إذا كان لديك مشاكل في الاعصاب. لا ينبغي أن يستخدم سيبروماكس في المرضى الذين لديهم تاريخ من مشكلة عصبية تسمى اعتلال الأعصاب الطرفية.</p><p>&middot; إذا كان لديك تاريخ من خلل بإيقاع القلب (عدم انتظام ضربات القلب).</p><p>مشاكل بالقلب:</p><p>&middot; يجب اتخاذ الحذر عند استخدام هذا النوع من الأدوية, وإذا كنت تعانى من إطالة الفاصل الزمنى QT عند ولادتك أو لديك تاريخ عائلي من إطالة الفاصل الزمنى QT (والذى يتضح من خلال رسم القلب الكهربائي والتسجيل الكهربائي للقلب), أو لديك اختلال فى توازن الأملاح في الدم (خاصةً انخفاض مستوى البوتاسيوم أو المغنسيوم في الدم) أو لديك بطء شديد فى ضربات القلب (وتسمى &#39;بطء القلب&#39;) أو مصاباً بضعف فى القلب (فشل القلب) أو لديك تاريخ من الأزمات القلبية (احتشاء عضلة القلب) أو إذا كنت من الإناث أو المسنين أو إذا كنت تتناول أدوية أخرى تتسبب فى تغيرات غير طبيعية فى رسم القلب الكهربائى (انظر فقرة تناول أدوية أخرى)</p><p>لعلاج بعض التهابات المسالك التناسلية, يمكن أن يصف لك الطبيب المعالج مضادات حيوية أخرى بالإضافة إلى سيبروماكس. وإذا لم يكن هناك أي تحسن في الأعراض بعد 3 أيام من العلاج, يرجى استشارة طبيبك المعالج.</p><p>اتصل بطبيبك المعالج فوراً فى حالة حدوث أى من الحالات الآتية أثناء تناول أقراص سيبروماكس. فسوف يقرر طبيبك المعالج ما إذا كنت تحتاج إلى التوقف عن تناول علاجك من أقراص سيبروماكس.</p><p>&middot; تفاعلات تحسسية حادة ومفاجئة (صدمة فرط الحساسية أو وذمة وعائية). حتى مع تناول الجرعة الأولى, هناك احتمالية بسيطة لتعرضك لتفاعلات تحسسية شديدة مع ظهور الأعراض التالية: ضيق في الصدر, وشعور بالدوار وإعياء أو إغماء, أو التعرض لدوخة عند الوقوف. إذا حدث لك ذلك, توقف عن تناول أقراص سيبروماكس واتصل بطبيبك المعالج فوراً.</p><p>&middot; قد يحدث ألم وتورم في المفاصل والتهاب الأوتار في بعض الأحيان, خاصةً إذا كنت من كبار السن وتخضع أيضاً للعلاج بالكورتيكوستيرويدات. التهاب وتمزق الأوتار قد يحدث حتى خلال ال 48 ساعة الأولى من العلاج أو ما يصل إلى عدة أشهر بعد التوقف عن العلاج بأقراص سيبروماكس. في أول بادرة لظهور أي ألم أو التهاب, توقف عن تناول أقراص سيبروماكس وامتثل لراحة المنطقة المؤلمة. تجنب أي ممارسة لتمارين ليس لها داعى, لأن ذلك قد يزيد من خطر تمزق الوتر.</p><p>&middot; إذا كنت تعاني من مرض الصرع أو أى حالات عصبية أخرى مثل نقص التروية الدماغية أو السكتة الدماغية, فقد تتعرض إلى الأعراض الجانبية المرتبطة بالجهاز العصبي المركزي. إذا حدث لك ذلك, توقف عن تناول أقراص سيبروماكس واتصل بطبيبك المعالج فوراً.</p><p>&middot; قد تتعرض إلى ردود أفعال نفسية عند تناول أقراص سيبروماكس لأول مرة. إذا كنت تعاني من الاكتئاب أو الذهان, قد تصبح الأعراض أسوأ عند العلاج بأقراص سيبروماكس. في حالات نادرة, قد يتطور الاكتئاب أو الذهان إلى ظهور الأفكار الانتحارية ومحاولات الانتحار أو إتمام الانتحار. إذا حدث ذلك, توقف عن تناول أقراص سيبروماكس واتصل بطبيبك المعالج فوراً.</p><p>&middot; قد تواجهك أعراض الاعتلال العصبي مثل ألم, حرقان, نخز, وتنميل و / أو ضعف. إذا حدث ذلك, توقف عن تناول أقراص سيبروماكس واتصل بطبيبك المعالج فوراً.</p><p>&middot; قد يؤدي تناول مجموعة من المضادات الحيوية والتي تعرف باسم الكينولونات الي الاصابة بتلف دائم للأعصاب.</p><p>&middot; قد تتعرض إلى الإسهال أثناء تناول المضادات الحيوية, بما فيها أقراص سيبروماكس, أو حتى بعد التوقف عن تناول المضادات الحيوية بعدة أسابيع. إذا أصبح الإسهال لديك شديداً أو مستمراً أو إذا لاحظت ظهور دم أو مخاط فى البراز, توقف عن تناول أقراص سيبروماكس فوراً, حيث أن ذلك قد يهدد حياتك. ولا تقم بتناول الأدوية التى تعمل على إيقاف أو إبطاء حركة الأمعاء واتصل بطبيبك المعالج فى الحال.</p><p>&middot; أخبر طبيبك المعالج أو فريق العمل بالمعمل بأنك تتناول أقراص سيبروماكس إذا كنت ستخضع لاختبار عينة دم أو بول.</p><p>&middot; إذا كنت تعانى من مشاكل بالكلى, أخبر طبيبك المعالج فقد يتطلب ذلك ضبط الجرعة الخاصة بحالتك.</p><p>&middot; أقراص سيبروماكس قد تسبب تلف بالكبد. إذا لاحظت ظهور أى أعراض مثل فقدان الشهية أو اليرقان (اصفرار الجلد), أو تحول لون البول إلى اللون القاتم أو حكة أو ألم بالمعدة, توقف عن تناول أقراص سيبروماكس واتصل بطبيبك المعالج فوراً.</p><p>&middot; أقراص سيبروماكس قد تتسبب فى خفض عدد خلايا الدم البيضاء لديك مما يقلل من مقاومتك للإصابة بالعدوى. إذا تعرضت لعدوى مع ظهور أعراض مثل الحمى والتدهور الحاد بشكل عام لحالتك أو حمى مع ظهور أعراض موضعية مثل التهاب الحلق/ البلعوم/ الفم أو مشاكل بولية يجب عليك زيارة طبيبك المعالج فى الحال. فسوف تؤخذ منك عينة دم لفحص النقص فى عدد خلايا الدم البيضاء (ندرة المحببات). لذلك, من الضرورى عليك إخبار طبيبك المعالج بالدواء الخاص بك.</p><p>&middot; أخبر طبيبك المعالج إذا كان من المعروف لديك أنك أو أحد أفراد عائلتك لديهم نقص في الجلوكوز 6 فوسفات نازعة الهيدروجين (G6PD), حيث أنك قد تواجه خطر الإصابة بفقر الدم مع سيبروماكس.</p><p>&middot; قد يصبح جلدك أكثر حساسية لضوء الشمس أو للآشعة فوق البنفسجية أثناء تناولك لأقراص سيبروماكس. لذلك, تجنب التعرض لأشعة الشمس القوية, أو ضوء الآشعة فوق البنفسجية الاصطناعي مثل أجهزة اسمرار البشرة.</p><p>تناول أدوية أخرى:</p><p>فضلاً أخبر طبيبك المعالج أو الصيدلى بشأن أى أدوية تتناولها أو تناولتها مؤخراً, بما فيها تلك التى حصلت عليها بدون وصفة طبية.</p><p>يجب أن تخبر طبيبك المعالج إذا كنت تتناول أدوية أخرى قد تغير فى إيقاع القلب لديك: الأدوية التى تنتمى إلى مجموعة الأدوية المضادة للخلل فى إيقاع القلب (مثل كينيدين, هيدروكينيدين, ديسوبيراميد, أميودارون, سوتالول, دوفيتيليد, إيبوتيليد), مضادات الاكتئاب ثلاثية الحلقات, بعض مضادات الجراثيم (التي تنتمي إلى مجموعة الماكروليدات), وبعض مضادات الذهان.</p><p>لا تقم بتناول أقراص سيبروماكس بالتزامن مع تيزانيدين, حيث أن ذلك قد يسبب أعراضاً جانبية مثل انخفاض ضغط الدم والنعاس (انظر الفقرة 2: &quot;لا تقم بتناول أقراص سيبروماكس فى الحالات الآتية&quot;).</p><p>من المعروف أن الأدوية التالية تتفاعل مع أقراص سيبروماكس فى جسمك. تناول أقراص سيبروماكس مع هذه الأدوية جنباً إلى جنب قد يؤثر على التأثير العلاجى لتلك الأدوية. وقد يزيد أيضاً من احتمالية الإصابة بالأعراض الجانبية.</p><p>أخبر طبيبك المعالج إذا كنت تتناول أى مما يلى:</p><p>&nbsp;</p><p>&middot; مشتقات الزانثين مثل الثيوفيلين (التي تستخدم لعلاج الربو).</p><p>&middot; فينيتوين (المستخدم في علاج الصرع).</p><p>&middot; أى أدوية تعمل على زيادة سيولة الدم المعروفة باسم (مضادات التخثر مثل الوارفارين).</p><p>&middot; سيكلوسبورين (الذي يستخدم لعلاج الصدفية, التهاب الجلد, التهاب المفاصل الروماتويدي وزرع الأعضاء).</p><p>&middot; جليبينكلاميد (دواء عن طريق الفم يستخدم لعلاج مرض السكر).</p><p>&middot; بروبينسيد (الذي يستخدم للوقاية من النقرس).</p><p>&middot; ميتوكلوبراميد (الذي يستخدم لعلاج الغثيان والقيء (الشعور بإعياء أو الإعياء) والصداع النصفى).</p><p>&middot; ميكسيليتين (الذي يستخدم لعلاج الخلل فى ضربات القلب).</p><p>&middot; روبينيرول (الذي يستخدم لعلاج مرض الشلل الرعاش).</p><p>&middot; ميثوتريكسيت (لعلاج أنواع معينة من السرطان, والصدفية, والتهاب المفاصل الروماتويدي).</p><p>&middot; تيزانيدين (لتشنج العضلات في التصلب المتعدد).</p><p>&middot; كلوزابين (مضاد للذهان).</p><p>&middot; أولانزابين (مضاد للذهان).</p><p>&middot; أدوية أخرى قد تغير فى إيقاع القلب لديك: الأدوية التى تنتمى إلى مجموعة الأدوية المضادة للخلل فى إيقاع القلب (مثل كينيدين, هيدروكينيدين, ديسوبيراميد, أميودارون, سوتالول, دوفيتيليد, إيبوتيليد), مضادات الاكتئاب ثلاثية الحلقات, وبعض مضادات الجراثيم (التي تنتمي إلى مجموعة الماكروليدات), وبعض مضادات الذهان.</p><p>&nbsp;</p><p>سيبروماكس قد يزيد من مستوى الأدوية الآتية فى الدم لديك:</p><p>&middot; بنتوكسيفيلين (لاضطرابات الدورة الدموية).</p><p>&middot; الكافيين.</p><p>&middot; دولوكسيتين (للاكتئاب, تلف الأعصاب السكري أو سلس البول).</p><p>&middot; ليدوكايين (لأمراض القلب أو الاستخدام كمخدر).</p><p>&middot; سيلدينافيل (لعلاج ضعف الانتصاب).</p><p>بعض الأدوية تقلل من تأثير أقراص سيبروماكس. أخبر طبيبك المعالج إذا كنت تتناول أو ترغب فى تناول أى مما يلى:</p><p>&middot; مضادات الحموضة.</p><p>&middot; أوميبرازول.</p><p>&middot; المكملات المعدنية.</p><p>&middot; سوكرالفيت.</p><p>&middot; موثق الفوسفات البوليمرية (مثل سيفيلامير).</p><p>&middot; الأدوية أو المكملات الغذائية التي تحتوي على الكالسيوم أو المغنسيوم أو الألومنيوم أو الحديد على سبيل المثال {أقراص ديدانوزين (العقاقير المضادة للفيروسات المستخدمة في علاج فيروس نقص المناعة البشرية)}</p><p>&nbsp;</p><p>إذا كانت هذه الأدوية ضرورية, قم بتناول أقراص سيبروماكس قبلها بحوالى ساعتين أو بعدها على الأقل بأربع ساعات.</p><p>تناول أقراص سيبروماكس مع الطعام والشراب</p><p>&nbsp;</p><p>إلا فى حالة تناولك لأقراص سيبروماكس أثناء وجبات الطعام, لا تأكل أو تشرب أي منتجات الألبان (مثل الحليب أو الزبادي) أو المشروبات التي تحتوي على الكالسيوم المضاف. حيث أنها قد تؤثر على امتصاص سيبروماكس وهكذا يجب أن تأخذ أقراص سيبروماكس الخاصة بك قبل تناول هذه المنتجات بساعة إلى ساعتين أو بعد تناولها على الأقل ب 4 ساعات.</p><p>الحمل والرضاعة</p><p>إنه من الأفضل تجنب استخدام أقراص سيبروماكس خلال فترة الحمل. أخبرى طبيبك المعالج إذا كنتِ حاملاً أو تخططين للحمل.</p><p>لا تقومى بتناول أقراص سيبروماكس خلال فترة الرضاعة, حيث أن مادة سيبروفلوكساسين تفرز مع اللبن وقد تلحق الضرر بطفلك.</p><p>استشيرى طبيبك المعالج أو الصيدلى قبل تناول أى أدوية أخرى.</p><p>القيادة واستخدام الآلات:</p><p>قد يجعلك سيبروماكس أقل تركيزاً. وقد تحدث بعض الآثار الجانبية العصبية. لذلك, من الضرورى أن تعرف مدى تأثير سيبروماكس عليك قبل قيادتك للسيارة أو استخدامك للآلات. فى حالة الشك, استشِر طبيبك المعالج بهذا الشأن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول أقراص سيبروماكس تماماً كما أخبرك الطبيب المعالج. يجب عليك التأكد من خلال طبيبك المعالج أو الصيدلى فى حالة عدم تأكدك.</p><p>يجب تناول الأقراص دائماً مع كمية كبيرة من الماء, حيث يساعد ذلك على الوقاية من تكون بلورات صغيرة في البول (بيلة البلورات).</p><p>يمكنك تناول الأقراص في أوقات الوجبات أو بين الوجبات. أى كالسيوم ستقوم بتناوله كجزء من وجبة الطعام لن يؤثر تأثيراً خطيراً على امتصاص الأقراص. بالرغم من ذلك, لا تقم بتناول أقراص سيبروماكس مع منتجات الألبان مثل اللبن أو الزبادى أو مع عصائر الفاكهة المزودة بالكالسيوم (مثل عصير البرتقال المزود بالكالسيوم).</p><p>أخبر طبيبك المعالج إذا كنت تعانى من مشاكل بالكلى, حيث سيتطلب ذلك ضبط الجرعة الخاصة بك. وسوف يعتمد تحديد الجرعة على نوع وحدة العدوى لديك وعمرك ووزنك ووظائف الكلى لديك.</p><p>البالغين</p><p>الجرعة المعتادة للبالغين هى ما بين 100- 750 ملجم مرتين يومياً. فى حالات عدوى الجهاز التنفسى تكون الجرعة المعتادة هى 500- 750 ملجم مرتين يومياً. في حالات عدوى المثانة والكلى, تكون الجرعة المعتادة هي 250- 500 ملجم مرتين يومياً. في السيلان, تكون الجرعة المعتادة هي 250- 500 ملجم كجرعة وحيدة. في الالتهابات المعدية المعوية, تكون الجرعة المعتادة هي 500 ملجم مرتين يومياً. في حالات العدوى داخل البطن, وعدوى الجلد والأنسجة الرخوة والعظام والتهابات المفاصل, وفي حالة المرضى المصابين بقلة العدلات تكون الجرعة المعتادة هي 500- 750 ملجم مرتين يومياً. في الإصابات التى تسببها بكتيريا التهاب السحايا النيسيري الجرعة المعتادة هي 500 ملجم كجرعة وحيدة. فى حالة التعرض لاستنشاق الجمرة الخبيثة تكون الجرعة المعتادة هي 500 ملجم مرتين يومياً.</p><p>المرضى كبار السن</p><p>سوف يقرر طبيبك المعالج الجرعة المناسبة لحالتك. وقد تكون جرعة أقل من تلك المعتادة فى حالة البالغين اعتماداً على مدى حدة العدوى لديك ووظائف الكلى الخاصة بك.</p><p>مشاكل الكلى/ الكبد</p><p>سوف يقرر طبيبك المعالج الجرعة المناسبة لحالتك اعتماداً على وظائف الكبد والكلى لديك. وهناك حاجة إلى تعليمات خاصة للجرعات فى حالة خضوعك للغسيل الكلوى أو وجود (الغسيل البريتوني المستمر).</p><p>الأطفال والمراهقين</p><p>لا يوصى باستخدام أقراص سيبروماكس بشكل عام للأطفال. بالرغم من ذلك فى بعض الحالات, قد يكون العلاج بهذه الأقراص مفيد للطفل وقد يقرر الطبيب المعالج علاج طفلك بهذا الدواء خاصةً فى حالات العدوى الآتية:</p><p>&middot; التليف الكيسي وتكون الجرعة المعتادة هى 20 ملجم/ كجم من وزن الجسم مرتين يومياً إلى أقصى جرعة يومية وهى 750 ملجم.</p><p>&middot; التهابات المسالك البولية المعقدة والتهاب الحويضة والكلية وتكون الجرعة المعتادة هي من 10 إلى 20 ملجم / كجم من وزن الجسم مرتين يومياً إلى حد أقصاه 750 ملجم في الجرعة الواحدة.</p><p>&middot; التعرض لاستنشاق الجمرة الخبيثة وتكون الجرعة المعتادة هى من 10 إلى 15 ملجم / كجم من وزن الجسم مرتين يومياً إلى حد أقصاه 500 ملجم في الجرعة الواحدة.</p><p>&middot; حالات أخرى من العدوى الحادة وتكون الجرعة المعتادة هى 20 ملجم / كجم من وزن الجسم مرتين يومياً إلى حد أقصاه 750 ملجم في الجرعة الواحدة.</p><p>لا تخطي أي جرعة من سيبروماكس ، أو تتوقف عن تناوله، حتى لو كنت تبدأ في الشعور بالتحسن، حتى الانتهاء من العلاج الموصوف لك إلا:</p><p>&bull; إذا كان لديك مشاكل في الأعصاب. انظر &quot;2. ما يجب مراعاته قبل تناول سيبروماكس&quot;</p><p>&bull; إذا كان لديك مشاكل في الجهاز العصبي المركزي. انظر &quot;2. ما يجب مراعاته قبل تناول سيبروماكس&quot;</p><p>من الهام جداً اتباع تعليمات الطبيب المعالج بشأن عدد الأقراص من سيبروماكس التى ينبغى عليك تناولها ومدى تكرار تناول هذه الأقراص وفترة العلاج. علماً بأن الفترة الزمنية المعتادة للعلاج هى ما بين 5 إلى 21 يوماً (على الرغم من أن هذا قد يكون أطول), اعتماداً على نوع وشدة العدوى.</p><p>فى حالة تناولك لأقراص سيبروماكس أكثر مما ينبغى</p><p>إذا تناولت أنت أو أى شخص آخر العديد من أقراص سيبروماكس أو إذا اعتقدت بقيام طفلك بابتلاع أى من هذه الأقراص, اتصل بطبيبك المعالج أو الصيدلى أو توجه إلى قسم الطوارئ بأقرب مستشفى فوراً. دائماً خذ معك الأقراص المتبقية وأيضاً علبة الدواء وهذه النشرة حيث يساعد ذلك الطبيب فى التعرف بشكل أسهل على الدواء الذى تناولته.</p><p>فى حالة نسيان تناول أقراص سيبروماكس</p><p>فى حالة نسيانك لتناول الجرعة الخاصة بك من أقراص سيبروماكس, تناولها حالما تتذكر. وإذا كان الوقت تقريباً قد حان لتناول الجرعة التالية, لا تقم بتناول الجرعة المفقودة وأكمل الجدول الزمنى لتناول الجرعات كما سبق. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية. واحرص دائماً على إكمال دورة العلاج.</p><p>فى حالة التوقف عن تناول أقراص سيبروماكس</p><p>من الهام جداً إتمام دورة العلاج حتى إذا بدأت تشعر بتحسن بعد أيام قليلة. حيث أنك إذا توقفت عن تناول هذا الدواء قبل الأوان قد يؤدى ذلك إلى عدم إتمام الشفاء من العدوى وعودة أو تدهور أعراض العدوى من جديد. أيضاً قد يعرضك ذلك إلى مقاومة البكتيريا للمضاد الحيوى. إذا كانت لديك أى أسئلة إضافية حول استخدام هذا الدواء, اسأل طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية, قد يسبب سيبروماكس أعراضاً جانبية وإن لم تحدث لكل من يتناول هذا الدواء. حوالى من 5- 14 % من المرضى يتعرضون للأعراض الجانبية ومعظم الأعراض الجانبية تشمل الأمعاء والجهاز العصبى.</p><p>فى حالة حدوث أى من الأعراض الآتية بعد وقت قليل من تناول الأقراص الخاصة بك من هذا الدواء, توقف عن تناول الأقراص وأخبر طبيبك المعالج فوراً. هذا النوع من التفاعلات نادر الحدوث وقد يعنى أنك تعانى من فرط التحسس تجاه الدواء:</p><p>&middot; طفح جلدي وحكة بالجلد أوطفح الجلد العقدي (&#39;الشرى&#39;), وحمى, وبقع حمراء صغيرة على الجسم, وزيادة الحساسية لآشعة الشمس أو تفاعلات جلدية شديدة ونادرة الحدوث جداً مثل بثور كبيرة مليئة بالسوائل, تقشير, وقروح. يمكن أيضاً أن تحدث تقرحات في الفم والحلق, وحول فتحة الشرج والمنطقة التناسلية وعلى سطح العينين.</p><p>&middot; أزيز مفاجئ أو ضيق في الصدر.</p><p>&middot; تورم في الجفون والوجه والشفاه أو الأوعية الدموية في الجلد.</p><p>&middot; غثيان وصداع</p><p>يجب عليك أيضاً إخبار طبيبك المعالج فوراً والتوقف عن تناول الأقراص إذا لاحظت أياً مما يلى:</p><p>&middot; ألم أو التهاب في الأوتار. هذا التأثير يحدث في حالات فردية. إذا واجهت هذه الأعراض يجب أن تتوقف عن تناول الأقراص, وامتثل لراحة الطرف المصاب واستشِر طبيبك المعالج فوراً.</p><p>&middot; إسهال شديد مع نزيف أو مخاط. هذا التأثير يحدث لأقل من واحد فى الألف شخص ولكنه يحدث لأكثر من واحد فى العشرة آلاف شخص.</p><p>&middot; شعور بأنك تريد إلحاق الأذى بنفسك. هذا التأثير يحدث فقط فى حالات فردية.</p><p>&middot; تغيرات في الإحساس وتلف الأعصاب (الاعتلال العصبي المحيطي الذي قد يصبح بشكل دائم) - ضرر يصيب الأعصاب في الذراعين واليدين والساقين والقدمين أو يمكن أن يحدث في الأشخاص الذين يتناولون الفلوروكينولونات، بما في ذلك السيبرو.</p><p>أعراض جانبية أخرى قد تحدث, وهى مذكورة أدناه:</p><p>أعراض جانبية شائعة (والتى يتعرض لها ما بين 1 إلى 10 أشخاص من كل 100 شخص)</p><p>&middot; غثيان, وإسهال.</p><p>&middot; ألم فى المفاصل عند الأطفال.</p><p>أعراض جانبية غير شائعة (والتى يتعرض لها ما بين 1 إلى 10 أشخاص من كل 1000 شخص)</p><p>&middot; عدوى فطرية.</p><p>&middot; ارتفاع تركيز الحمضات, وهو نوع من خلايا الدم البيضاء.</p><p>&middot; فقدان الشهية.</p><p>&middot; فرط النشاط أو الهياج</p><p>&middot; صداع, ودوخة, ومشاكل في النوم, أو اضطرابات فى حاسة التذوق.</p><p>&middot; قيء وآلام فى البطن ومشاكل في الجهاز الهضمي مثل اضطراب في المعدة (عسر الهضم / حرقة المعدة) وريح.</p><p>&middot; زيادة كميات بعض المواد في الدم (الترانساميناسات و / أو البيليروبين).</p><p>&middot; طفح جلدي, وحكة بالجلد أو الشرى.</p><p>&middot; ضعف وظيفة الكلى.</p><p>&middot; آلام في العضلات والعظام, والشعور بالإعياء (الوهن), أو حمى.</p><p>&middot; زيادة في الفوسفاتاز القلوي في الدم (وهى مادة معينة في الدم).</p><p>أعراض جانبية نادرة (والتى يتعرض لها ما بين 1 إلى 10 أشخاص من كل 10,000 شخص)</p><p>&middot; التهاب القولون المرتبط باستخدام المضاد الحيوى (وقد يكون قاتلاً فى حالات نادرة جداً) (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&middot; تغييرات فى تعداد الدم (نقص الكريات البيض, أو كثرة الكريات البيض, أو قلة العدلات, أو فقر الدم), وزيادة أو نقص كميات من عامل التخثر الدموي (خلايا تخثر الدم).</p><p>&middot; حساسية, وتورم (وذمة), أو تورم سريع فى الجلد والأغشية المخاطية (وذمة وعائية).</p><p>&middot; زيادة نسبة السكر في الدم (فرط سكر الدم).</p><p>&middot; ارتباك, وعدم تركيز وقلق, وأحلام غريبة, واكتئاب (مما قد يؤدي إلى أفكار انتحارية, ومحاولات الانتحار, أو إكمال الانتحار), أو الهلوسة.</p><p>&middot; إحساس بوخز إبر ودبابيس, وحساسية غير معتادة لمنبهات الحواس, انخفاض حساسية الجلد, ورعشات, ونوبات (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس). أو دوخة.</p><p>&middot; مشاكل فى البصر وتشمل ازوداج الرؤية.</p><p>&middot; طنين, وفقدان السمع, أوضعف السمع.</p><p>&middot; تسارع فى ضربات القلب.</p><p>&middot; توسع في الأوعية الدموية, وانخفاض ضغط الدم, أو الإغماء.</p><p>&middot; ضيق في التنفس, بما في ذلك أعراض الربو.</p><p>&middot; اضطرابات الكبد, واليرقان (اليرقان الركودي), أو التهاب الكبد.</p><p>&middot; الحساسية للضوء (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&middot; آلام في العضلات, والتهاب المفاصل, وزيادة التوتر العضلى, أو التشنج العضلى.</p><p>&middot; الفشل الكلوي, وظهور دم أو بلورات في البول (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس) والتهاب المسالك البولية.</p><p>&middot; احتباس السوائل أو التعرق المفرط.</p><p>&middot; زيادة مستويات إنزيم الأميليز.</p><p>أعراض جانبية نادرة جداً (والتى يتعرض لها أقل من شخص واحد من كل 10,000 شخص)</p><p>&middot; صداع نصفي, وخلل فى التنسيق, وعدم اتزان فى السير على الأقدام (اضطراب فى المشي), اضطراب في حاسة الشم, الضغط على المخ (الضغط داخل الجمجمة). &bull; نوع خاص من انخفاض تعداد خلايا الدم {(فقر الدم الانحلالي), وهو شكل من أشكال فقر الدم بسبب تحطيم خلايا الدم الحمراء،} قد تحدث مع اليرقان), وانخفاض خطير في نوع من خلايا الدم البيضاء (ندرة المحببات), انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية (قلة الكريات الشاملة), والتي قد تكون قاتلة, وحالة كسل فى نخاع العظم, والتي قد تكون قاتلة أيضاً (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&middot; تفاعلات تحسسية شديدة (رد فعل تحسسي أو صدمة فرط الحساسية, والتي يمكن أن تكون قاتلة) (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&middot; اضطرابات عقلية (ردود فعل ذهانية مما قد يؤدي إلى أفكار الانتحارية, ومحاولات الانتحار, أو إكمال الانتحار) (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&middot; تشوهات اللون البصرية</p><p>&middot; التهاب في جدار الأوعية الدموية (التهاب الأوعية الدموية)</p><p>&middot; التهاب البنكرياس</p><p>&middot; نمشات صغيرة , ونزيف تحت الجلد, مع طفح جلدي (على سبيل المثال, متلازمة ستيفنز جونسون والتى قد تكون قاتلة أو انحلال البشرة السمي)</p><p>&middot; ضعف العضلات, التهاب الأوتار, تمزق الأوتار - خصوصاً في وتر كبير في الجزء الخلفي من الكاحل (وتر العرقوب) (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس), تفاقم أعراض الوهن العضلي الوبيل (انظر الفقرة 2: ينبغى توخى الحذر مع أقراص سيبروماكس).</p><p>&nbsp;</p><p>أعراض جانبية معدل تكرارها غير معلوم (لا يستدل عليه من المعلومات المتاحة)</p><p>&middot; مشاكل متعلقة بالجهاز العصبى مثل ألم, حرقة, وخز, تنميل و/ أو ضعف فى الأطراف.</p><p>&middot; تسارع غير طبيعى فى ضربات القلب, وعدم انتظام فى إيقاع القلب قد يهدد الحياة, وتغير فى إيقاع القلب (يسمى &quot;إطالة الفترة الزمنية QT&quot; والذى يتضح من خلال رسم القلب الكهربائى ECG والنشاط الكهربى للقلب).</p><p>&middot; طفح بثرى.</p><p>&middot; تأثير على تخثر الدم (فى المرضى المعالجين بمضادات فيتامين k)</p><p>إذا أصبحت أى من هذه الأعراض الجانبية جسيمة, أو إذا لاحظت أى أعراض جانبية أخرى لم يتم ذكرها فى هذه النشرة, فضلاً أخبر طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ فى درجة حرارة أقل من 30 درجة مئوية.</p><p>يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</p><p>لا تستخدم هذه الأقراص بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p><p>لا يجب التخلص من الأدوية عبر مياه الصرف الصحى أو النفايات المنزلية. اسأل الصيدلى عن كيفية التخلص من الأدوية التى لم تعد بحاجة إليها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة:</p><p>سيبروماكس 500 ملجم أقراص مغطاة بطبقة رقيقة: كل قرص مغطى بطبقة رقيقة يحتوى على سيبروفلوكساسين هيدروكلورايد أحادى التميه بما يكافئ 500 ملجم من سيبروفلوكساسين كمادة فعالة.</p><p>مكونات أخرى وهى:</p><p>لب القرص: سيبروفلوكساسين هيدروكلورايد, أفيسيل PH 101, نشاء جليكولات الصوديوم, بوفيدون K-30, ثانى أكسيد السيليكون الغروانى وستيارات المغنسيوم.</p><p>غطاء القرص:</p><p>&middot; سيبروماكس 500 ملجم أقراص مغطاة بطبقة رقيقة:</p><p>أوبادرى30902 -L-YO أزرق.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>سيبروماكس 500 ملجم أقراص مغطاة بطبقة رقيقة: أقراص مستطيلة لونها أزرق فاتح ثنائية التحدب مغطاة بطبقة رقيقة محفور عليها &quot;150&quot;SP من جانب واحد وبها حد فاصل على الجانب الآخر. كل كرتونة تحتوى على 10 أقراص مغطاة بطبقة رقيقة فى شريط واحد. محتويات العبوة: سيبروماكس 500 ملجم أقراص مغطاة بطبقة رقيقة: &middot; تتوفر على شكل شرائط داخل عبوة. &middot; حجم العبوات: 10, 100 و1000 قرص مغطى بطبقة رقيقة. قد لا يتم تسويق جميع الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cipromax 500 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cipromax 500 mg (as ciprofloxacin hydrochloride).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
Light blue oblong, biconvex film-coated tablets engraved with "SP 150" on one side and
breakline on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cipromax film-coated tablets are indicated for the treatment of the following infections (see<br />sections 4.4 and 5.1). Special attention should be paid to available information on resistance<br />to ciprofloxacin before commencing therapy.<br />Consideration should be given to official guidance on the appropriate use of antibacterial<br />agents.<br />&nbsp;</p><p><u>Adults</u><br />&bull; Lower respiratory tract infections due to Gram-negative bacteria</p><p>- exacerbation of chronic obstructive pulmonary disease. In exacerbation of<br />chronic obstructive pulmonary disease Ciprofloxacin should be used only<br />when it is considered inappropriate to use other antibacterial agents that are<br />commonly recommended for the treatment of these infections.<br />- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis.<br />- Pneumonia.</p><p>&bull; Chronic suppurative otitis media.<br />&bull; Acute exacerbation of chronic sinusitis especially if these are caused by Gramnegative<br />bacteria.</p><p>&bull; Urinary tract infections<br />- Uncomplicated acute cystitis.<br />In uncomplicated acute cystitis Cipromax film-coated tablets should be used only<br />when it is considered inappropriate to use other antibacterial agents that are<br />commonly recommended for the treatment of these infections.<br />- Acute pyelonephritis.<br />- Complicated Urinary tract infections.<br />- Bacterial prostatitis.</p><p>&bull; Genital tract infections<br />- gonococcal uretritis and cervicitis due to susceptible Neisseria gonorrhoeae.<br />- epididymo-orchitis including cases due to susceptible Neisseria gonorrhoeae.<br />- pelvic inflammatory disease including infections due to susceptible Neisseria<br />gonorrhoeae.</p><p>&bull; Infections of the gastro-intestinal tract (e.g. travellers&#39; diarrhoea).<br />&bull; Intra-abdominal infections.<br />&bull; Infections of the skin and soft tissue caused by Gram-negative bacteria.<br />&bull; Infections of the bones and joints.<br />&bull; Prophylaxis of invasive infections due to Neisseria meningitides.<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment).<br />Cipromax may be used in the management of neutropenic patients with fever that is<br />suspected to be due to a bacterial infection.</p><p><u>Children and adolescents</u><br />&bull; Broncho-pulmonary infections due to Pseudomonas aeruginosa in patients with<br />cystic fibrosis.<br />&bull; Complicated urinary tract infections and acute pyelonephritis<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Cipromax may also be used to treat severe infections in children and adolescents when this<br />is considered to be necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of<br />cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology </strong></p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>Treatment of infections due to certain bacteria (e.g. <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter </em>or <em>Staphylococci) </em>may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><em><u>Adults</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:599px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top"><p>Acute exacerbation of chronic sinusitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malignant external otitis</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td><td style="vertical-align:top"><p>28 days up to 3 months</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Urinary tract infections (see section 4.4)</p></td><td rowspan="2" style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily to 500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>In pre-menopausal women, 500 mg single dose may be used</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Complicated cystitis, Acute pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Complicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Bacterial Prostatitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks (acute) to 4 to 6 weeks (chronic)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Genital tract infections</p></td><td style="vertical-align:top"><p>Gonococcal uretritis and cervicitis due to susceptible Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Epididymo-orchitis and pelvic inflammatory diseases including cases due to susceptible Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections of the gastro-intestinal tract and intra-abdominal infections</p></td><td style="vertical-align:top"><p>Diarrhoea caused by bacterial pathogens including <em>Shigella </em>spp. other than <em>Shigella dysenteriae</em> type 1 and empirical treatment of severe travellers&#39; diarrhoea</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1 day</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by <em>Shigella dysenteriae</em> type 1</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>5 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by <em>Vibrio cholerae</em></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Typhoid fever</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>5 to 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the skin and soft tissue caused by Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>max. of 3 months</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neutropenic patients with fever suspected to be due to a bacterial infection.</p><p>Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>Therapy should be continued over the entire period of neutropenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prophylaxis of invasive infections due to Neisseria meningitidis</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>60 days from the confirmation of <em>Bacillus anthracis</em> exposure</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><em><u>Paediatric population</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td></tr><tr><td style="vertical-align:top"><p>cystic fibrosis</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections and pyelonephritis</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose.</p></td><td style="vertical-align:top"><p>60 days from the confirmation of <em>Bacillus anthracis</em> exposure</p></td></tr><tr><td style="vertical-align:top"><p>Other severe infections</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>According to the type of infections</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Elderly patients </u></em></p><p>Geriatric patients should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance.</p><p><em><u>Patients with renal and hepatic impairment</u></em></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance</strong></p><p><strong>[mL/min/1.73 m&sup2;]</strong></p></td><td style="vertical-align:top"><p><strong>Serum Creatinine</strong></p><p><strong>[&micro;mol/L]</strong></p></td><td style="vertical-align:top"><p><strong>Oral Dose</strong></p><p><strong>[mg]</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>&lt; 124</p></td><td style="vertical-align:top"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>124 to 168</p></td><td style="vertical-align:top"><p>250-500 mg every 12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h (after dialysis)</p></td></tr><tr><td style="vertical-align:top"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><em><u>Method of administration</u></em></p><p>Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Cipromax tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice) (see section 4.5).</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1. 
•	Concomitant administration of ciprofloxacin and tizanidine (see section 4.5). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of ciprofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with ciprofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).</p><p><u>Severe infections and mixed infections with Gram-positive and anaerobic pathogens</u></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.</p><p><u>Streptococcal Infections (including Streptococcus pneumoniae)</u></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.</p><p><u>Genital tract infections</u></p><p>Gonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant <em>Neisseria gonorrhoeae</em> isolates.</p><p>Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitis only if ciprofloxacin-resistant <em>Neisseria gonorrhoeae</em> can be excluded.</p><p>For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant <em>Neisseria gonorrhoeae</em> can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><u>Urinary tract infections </u></p><p>Resistance to fluoroquinolones of <em>Escherichia coli</em>&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in <em>Escherichia coli</em> to fluoroquinolones.</p><p>The single dose of ciprofloxacin that may be used in uncomplicated cystitis in pre-menopausal women is expected to be associated with lower efficacy than with the longer treatment duration. This is all the more to be taken into account as regards the increasing resistance level of <em>Escherichia coli</em> to quinolones.</p><p><u>Intra-abdominal infections</u></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.</p><p><u>Travellers&#39; diarrhoea</u></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><u>Infections of the bones and joints </u></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><em><u>Inhalational anthrax</u></em></p><p>Use in humans is based on <em>in-vitro</em> susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><u>Paediatric population</u></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue. (see section 4.8).</p><p><u>Broncho-pulmonary infections in cystic fibrosis </u></p><p>Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><u>Complicated urinary tract infections and pyelonephritis</u></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1-17 years.</p><p><u>Other specific severe infections</u></p><p>Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p><u>Prolonged, disabling and potentially irreversible serious adverse drug reactions </u></p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. Cipromax should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p><u>Tendinitis and tendon rupture </u></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of ciprofloxacin therapy. The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, or in patients concomitantly treated with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.</p><p>At the first sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued, and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur. &nbsp;</p><p><u>Patients with myasthenia gravis</u></p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis because symptoms can be exacerbated (see section 4.8).</p><p><u>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence </u></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet&#39;s disease, hypertension, rheumatoid arthritis) or additionally</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&#39;s syndrome) or additionally</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p><p><u>Vision disorders </u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><u>Photosensitivity</u></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><u>Seizures</u></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8).</p><p><u>Peripheral neuropathy </u><u>&nbsp;</u></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with ciprofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8).</p><p><u>Psychiatric reactions </u></p><p>Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued.</p><p><u>Cardiac disorders</u></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><ul><li>congenital long QT syndrome.</li><li>concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia).</li><li>cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</li></ul><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p>&nbsp;</p><p><u>Dysglycaemia </u></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported (see section 4.8), usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.</p><p><u>Gastrointestinal System</u></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p><u>Renal and urinary system</u></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><u>Impaired renal function </u></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><u>Hepatobiliary system</u></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><u>Glucose-6-phosphate dehydrogenase deficiency</u></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.</p><p><u>Resistance</u></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by <em>Staphylococcus</em> and <em>Pseudomonas</em> species.</p><p><u>Cytochrome P450</u></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine). Co-administration of ciprofloxacin and tizanidine is contra-indicated. Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co-administration of ciprofloxacin and tizanidine is contra-indicated.</p><p><u>Methotrexate</u></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><u>Interaction with tests</u></p><p>The <em>in-vitro</em> activity of ciprofloxacin against <em>Mycobacterium tuberculosis</em> might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other products on ciprofloxacin:</u></p><p><u>Drugs known to prolong QT interval</u></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p><u>Chelation Complex Formation</u></p><p>The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p><u>Food and Dairy Products</u></p><p>Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.</p><p><u>Probenecid</u></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><u>Metoclopramide</u></p><p>Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.</p><p><u>Omeprazole</u></p><p>Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of C<sub>max</sub> and AUC of ciprofloxacin.</p><p><u>Effects of ciprofloxacin on other medicinal products:</u></p><p><u>Tizanidine</u></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (C<sub>max</sub> increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><u>Methotrexate</u></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><u>Theophylline</u></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p><u>Other xanthine derivatives</u></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><u>Phenytoin</u></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><u>Cyclosporin</u></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><u>Vitamin K antagonists </u></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).</p><p><u>Duloxetine</u></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and C<sub>max</sub> of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><u>Ropinirole</u></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of C<sub>max</sub> and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p><u>Lidocaine</u></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><u>Clozapine</u></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><u>Sildenafil</u></p><p>C<sub>max</sub> and AUC of sildenafil were increased approximately two fold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><u>Agomelatine</u></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see &#39;Cytochrome P450&#39; in section 4.4).</p><p><u>Zolpidem</u></p><p>Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><u>Breast-feeding</u></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td><p>The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.</p><p>ADRs derived from clinical studies and post-marketing surveillance with ciprofloxacin (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&ge; 1/1,000 to</p><p>&lt; 1/100</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&ge; 1/10,000 to</p><p>&lt; 1/1,000</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>&lt; 1/10,000</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p>(cannot be estimated from available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mycotic superinfections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Anaemia</p><p>Neutropenia</p><p>Leukocytosis</p><p>Thrombocytopenia</p><p>Thrombocytaemia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Agranulocytosis</p><p>Pancytopenia (life-threatening)</p><p>Bone marrow depression (life-threatening)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction</p><p>Allergic oedema / angiooedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Anaphylactic shock (life-threatening) (see section 4.4)</p><p>Serum sickness-like reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemia (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;Hypoglycaemic coma (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Psychomotor hyperactivity / agitation</p></td><td style="vertical-align:top"><p>Confusion and disorientation</p><p>Anxiety reaction</p><p>Abnormal dreams</p><p>Depression (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p>Hallucinations</p></td><td style="vertical-align:top"><p>Psychotic reactions (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide)</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;Mania, hypomania</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p><p>Sleep disorders</p><p>Taste disorders</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Hypoaesthesia</p><p>Tremor</p><p>Seizures (including status epilepticus see section 4.4)</p><p>Vertigo</p></td><td style="vertical-align:top"><p>Migraine</p><p>Disturbed coordination</p><p>Gait disturbance</p><p>Olfactory nerve disorders</p><p>Intracranial hypertension and psuedotumor cerebri</p></td><td style="vertical-align:top"><p>Peripheral neuropathy and polyneuropathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances (e.g. diplopia)</p></td><td style="vertical-align:top"><p>Visual colour distortions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing loss / Hearing impaired</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong>**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular arrhythmia, and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see section 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong>**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p><p>Hypotension</p><p>Syncope</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respirator, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;Antibiotic associated diarrhoea including pseudomembraneous colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in transaminases</p><p>Increased bilirubin</p></td><td style="vertical-align:top"><p>Hepatic impairment</p><p>Cholestatic icterus</p><p>Hepatitis</p></td><td style="vertical-align:top"><p>Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Petechiae</p><p>Erythema multiforme</p><p>Erythema nodosum</p><p>Stevens-Johnson syndrome (potentially life-threatening)</p><p>Toxic epidermal necrolysis (potentially life-threatening)</p></td><td style="vertical-align:top"><p>Acute generalised exanthematous pustulosis (AGEP),</p><p>&nbsp;Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal, Connective Tissue and Bone Disorders</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskeletal pain (e.g. extremity pain, back pain, chest pain)</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthritis</p><p>Increased muscle tone and cramping</p></td><td style="vertical-align:top"><p>Muscular weakness</p><p>Tendinitis</p><p>Tendon rupture (predominantly Achilles tendon) (see section 4.4)</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Renal failure</p><p>Haematuria</p><p>Crystalluria (see section 4.4)</p><p>Tubulointerstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Fever</p></td><td style="vertical-align:top"><p>Oedema</p><p>Sweating (hyperhidrosis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Increased amylase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>International normalised ratio increased (in patients treated with Vitamin K antagonists)</p></td></tr></tbody></table><p>*Very rare case of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rapture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment in hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p><u>Paediatric population </u></p><p>The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p><strong>Reporting of suspected adverse reactions </strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>For Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999.</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>For UAE:</strong></p><p>Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853&nbsp;</p><p>Tel: 80011111</p><p>Email:&nbsp;pv@mohap.gov.ae</p><p>Drug Department<br />Ministry of Health &amp; Prevention,</p><p>Dubai, UAE.</p><p><strong>For OMAN</strong>:</p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: dg-padc@moh.gov.om</p><p>Website:&nbsp;<u>www.moh.gov.om</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated.</p><p>Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses.</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02</p><p><u>Mechanism of action:</u></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><u>Pharmacokinetic/pharmacodynamic relationship:</u></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (C<sub>max</sub>) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><u>Mechanism of resistance:</u></p><p>In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in-vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.</p><p>Plasmid-mediated resistance encoded by qnr-genes has been reported<em>.</em></p><p><u>Spectrum of antibacterial activity:</u></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p><em><u>EUCAST Recommendations</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Salmonella spp.</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas </em>spp.</p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter </em>spp.</p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>S &le; 0.125 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.03 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related breakpoints<strong>*</strong></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1 <em>Staphylococcus</em> spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p></td></tr></tbody></table><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for <em>Streptococcus</em> species see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Bacillus anthracis</em> (1)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Aeromonas </em>spp.</p><p><em>Brucella </em>spp.</p><p><em>Citrobacter koseri</em></p><p><em>Francisella tularensis</em></p><p><em>Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae*</em></p><p><em>Legionella </em>spp.</p><p><em>Moraxella catarrhalis*</em></p><p><em>Neisseria meningitidis</em></p><p><em>Pasteurella </em>spp.</p><p><em>Salmonella </em>spp.<em>*</em></p><p><em>Shigella </em>spp.<em>*</em></p><p><em>Vibrio </em>spp.</p><p><em>Yersinia pestis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Mobiluncus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Chlamydia trachomatis</em> ($)</p><p><em>Chlamydia pneumoniae</em> ($)</p><p><em>Mycoplasma hominis</em> ($)</p><p><em>Mycoplasma pneumoniae</em> ($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis </em>($)</p><p><em>Staphylococcus</em> spp.<em> *</em>(2)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumannii<sup>+</sup></em></p><p><em>Burkholderia cepacia<sup>+</sup>*</em></p><p><em>Campylobacter </em>spp.<em><sup>+</sup>*</em></p><p><em>Citrobacter freundii*</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae*</em></p><p><em>Escherichia coli*</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae*</em></p><p><em>Morganella morganii*</em></p><p><em>Neisseria gonorrhoeae*</em></p><p><em>Proteus mirabilis*</em></p><p><em>Proteus vulgaris*</em></p><p><em>Providencia </em>spp.</p><p><em>Pseudomonas aeruginosa*</em></p><p><em>Pseudomonas fluorescens</em></p><p><em>Serratia marcescens*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Peptostreptococcus </em>spp.</p><p><em>Propionibacterium acnes</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Actinomyces</em></p><p><em>Enteroccus faecium</em></p><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Excepted as listed above</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Mycoplasma genitalium</em></p><p><em>Ureaplasma urealitycum</em></p></td></tr><tr><td style="vertical-align:top"><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p><sup>+ </sup>Resistance rate &ge; 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of <em>Bacillus anthracis</em> spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on <em>in-vitro</em> susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.</p><p>(2): Methicillin-resistant <em>S. aureus</em> very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration of single doses of 250 mg, 500 mg and 750 mg of Cipromax tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.</p><p>Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (C<sub>max</sub>) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.</p><p>The absolute bioavailability is approximately 70-80%.</p><p>A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.</p><p><u>Distribution</u></p><p>Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><u>Biotransformation</u></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display <em>in-vitro</em> antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><u>Elimination</u></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Excretion of ciprofloxacin (% of dose)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral Administration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Urine</strong></p></td><td style="vertical-align:top"><p><strong>Faeces</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>44.7</p></td><td style="vertical-align:top"><p>25.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolites (M<sub>1</sub>-M<sub>4</sub>)</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>7.5</p></td></tr></tbody></table><p>Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><u>Paediatric patients</u></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children C<sub>max</sub> and AUC were not age-dependent (above one year of age). No notable increase in C<sub>max</sub> and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis C<sub>max</sub> was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin <em>in-vitro</em> and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p><u>Articular tolerability: </u></p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Excipients:</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Tablet Core:</strong> Avicel PH 101, Sodium Starch Glycollate, Povidone K-30, Colloidal Silicon Dioxide and Magnesium Stearate.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Coating Material:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Opadry OY-L-30902 Blue</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                60 months (5 years).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Do not store above 30&deg;C.</p><p>Keep in the original container.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent thermoformed PVC/PVDC blister.</p><p>Each pack of&nbsp;CIPROMAX&nbsp;contains 1 Blister per unit carton (10 Tablets/ Blister).</p><p>Hard tempered aluminium foil lid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>